In conclusion, our findings establish a novel link between sEH and NLRP3 inflammasome activation in DKD pathogenesis, highlighting sEH inhibition as a promising therapeutic strategy for DKD treatment. This evidence concerns the gene EPHX2 and diabetic kidney disease.